{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Cytokine storm",
      "Group A streptococcus",
      "Necrotizing fasciitis",
      "Staphylococcus aureus",
      "Superantigen",
      "Toxic shock syndrome"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "23830657",
  "DateCompleted": {
    "Year": "2013",
    "Month": "10",
    "Day": "21"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "03",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.ccc.2013.03.012",
      "S0749-0704(13)00029-8"
    ],
    "Journal": {
      "ISSN": "1557-8232",
      "JournalIssue": {
        "Volume": "29",
        "Issue": "3",
        "PubDate": {
          "Year": "2013",
          "Month": "Jul"
        }
      },
      "Title": "Critical care clinics",
      "ISOAbbreviation": "Crit Care Clin"
    },
    "ArticleTitle": "Toxic shock syndrome: major advances in pathogenesis, but not treatment.",
    "Pagination": {
      "StartPage": "651",
      "EndPage": "675",
      "MedlinePgn": "651-75"
    },
    "Abstract": {
      "AbstractText": [
        "Toxic shock syndrome (TSS) is primarily the result of a superantigen-mediated cytokine storm and M protein-mediated neutrophil activation, resulting in the release of mediators leading to respiratory failure, vascular leakage, and shock. Mortality for streptococcal TSS still hovers at 50%. There is evidence to support a role for intravenous immunoglobulin (IVIG) in the treatment of streptococcal TSS. An observational study suggests that an initial conservative surgical approach combined with the use of immune modulators, such as IVIG, may reduce the morbidity associated with extensive surgical exploration in hemodynamically unstable patients without increasing mortality."
      ],
      "CopyrightInformation": "Copyright \u00a9 2013 Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology, Mount Sinai Hospital, University Health Network, University of Toronto, 600 University Avenue, Room 1487, Toronto, Ontario M5G 1X5, Canada. delow@mtsinai.on.ca"
          }
        ],
        "LastName": "Low",
        "ForeName": "Donald E",
        "Initials": "DE"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Crit Care Clin",
    "NlmUniqueID": "8507720",
    "ISSNLinking": "0749-0704"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cytokines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunoglobulins, Intravenous"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Cytokines"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "microbiology"
      ],
      "DescriptorName": "Fasciitis, Necrotizing"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Immunoglobulins, Intravenous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Incidence"
    },
    {
      "QualifierName": [
        "adverse effects",
        "microbiology"
      ],
      "DescriptorName": "Menstrual Hygiene Products"
    },
    {
      "QualifierName": [
        "drug effects",
        "isolation & purification",
        "pathogenicity"
      ],
      "DescriptorName": "Methicillin-Resistant Staphylococcus aureus"
    },
    {
      "QualifierName": [
        "complications",
        "microbiology"
      ],
      "DescriptorName": "Pneumonia, Bacterial"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "immunology",
        "microbiology"
      ],
      "DescriptorName": "Shock, Septic"
    },
    {
      "QualifierName": [
        "complications",
        "microbiology"
      ],
      "DescriptorName": "Skin Diseases"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "immunology",
        "microbiology"
      ],
      "DescriptorName": "Staphylococcal Infections"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "isolation & purification",
        "pathogenicity"
      ],
      "DescriptorName": "Staphylococcus aureus"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "immunology",
        "microbiology"
      ],
      "DescriptorName": "Streptococcal Infections"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology",
        "isolation & purification",
        "pathogenicity"
      ],
      "DescriptorName": "Streptococcus pyogenes"
    },
    {
      "QualifierName": [
        "complications",
        "microbiology"
      ],
      "DescriptorName": "Wound Infection"
    }
  ]
}